Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
67 results about "Prolyl-Hydroxylase Inhibitors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compounds that inhibit the action of HYDROXYLASES that act on PROLINE to form HYDROXYPROLINE.
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SMITHKLINE BECKMAN CORP
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SMITHKLINE BECKMAN CORP
Isoquinolone compound and application thereof
The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
ActiveUS20110077267A1Easy to produceReduce productionBiocideGroup 5/15 element organic compoundsDiseaseMedicine
The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]:wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.
Owner:JAPAN TOBACCO INC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Quinazolinones as prolyl hydroxylase inhibitors
Quinazolinone compounds of formula (I) are described,which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
Owner:JANSSEN PHARMA NV
Compositions and methods for treating anemia
PendingUS20160143891A1Raise serum hemoglobinRiskHeavy metal active ingredientsBiocideDosing regimenNephrosis
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Owner:AKEBIA THERAPEUTICS
Prolyl hydroxylase inhibitors
Owner:GLAXO SMITHKLINE LLC
Spiroindalones
ActiveUS20100137297A1Increase productionReduce productionBiocideOrganic chemistryHif prolyl hydroxylaseProlyl Hydroxylases
The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SMITHKLINE BECKMAN CORP
Compositions and Methods for Treating Anemia
ActiveUS20180092892A1Reduced average total daily doseOrganic chemistryAmide active ingredientsRegimenNon dialysis dependent
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Owner:AKEBIA THERAPEUTICS
4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
Owner:JANSSEN PHARMA NV
Quinazolinones as prolyl hydroxylase inhibitors
Quinazolinone compounds of formula (I) are described,which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
Owner:JANSSEN PHARMA NV
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain quinoxaline-5-carboxamide derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Novel 1,8-naphthyridine compounds
The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK & CO INC
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Benzoimidazoles as prolyl hydroxylase inhibitors
The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
Owner:JANSSEN PHARMA NV
Novel 1.8-naphthyridine compounds
InactiveUS20100056563A1Increased endogenous productionReduced endogenous productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase
The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME CORP
Prolyl Hydroxylase Inhibitors
InactiveUS20110160227A1Increase productionOrganic active ingredientsBiocideDiseaseProlyl Hydroxylases
The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:SHAW ANTONY +1
Prolylhydroxylase inhibitors and methods of use
Owner:CORNELL UNIVERSITY
Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
ActiveUS8283465B2Organic active ingredientsGroup 5/15 element organic compoundsMedicineTriazolopyridine
The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]:wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.
Owner:JAPAN TOBACCO INC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Prolyl Hydroxylase Inhibitors
InactiveUS20100298324A1Increase productionBiocideOrganic active ingredientsDiseaseHif prolyl hydroxylase
The invention described herein relates to certain 4-oxo-2-thioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Substituted pyrimidines
The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
Owner:MERCK SHARP & DOHME LLC +2
Prolyl Hydroxylase Inhibitors
The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Quinazolinones as prolyl hydroxylase inhibitors
Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
Owner:JANSSEN PHARMA NV
Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]:wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.
Owner:JAPAN TOBACCO INC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITHKLINE LLC
Prolyl hydroxylase inhibitors
The invention described herein relates to certain benzimidazol-4-ylcarboxamide derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Owner:GLAXO SMITH KLINE A CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com